| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
GT103 (50 μg/mL; overnight) can bind to formalin-fixed, paraffin-embedded human non-small cell lung cancer (NSCLC) tumor tissue sections, but has no significant binding to formalin-fixed, paraffin-embedded normal human lung tissue sections [1]. GT103 (200 μg/mL; 2 hours) can increase plasma membrane calreticulin expression by about 2-fold in NCI-H460 and A549 human lung cancer cells, while the total calreticulin level of cells remains unchanged [1]. GT103 (200 μg/mL; 24 hours) can significantly increase the deposition of C3b/iC3b on NCI-H460 and A549 human lung cancer cells via the classical complement pathway, with reduced deposition in C1q-depleted serum, but no reduction in deposition in factor B-depleted serum [1]. GT103 (200 μg/mL; 2 h) significantly enhanced the binding of C1q to the surface of NCI-H460 human lung cancer cells, an effect dependent on the Fc region of the antibody [1]. GT103 (250 μg/mL; 4 h) significantly enhanced macrophage-mediated in vitro antibody-dependent phagocytosis (ADCP) of NCI-H460 human lung cancer cells [1]. GT103 (200 μg/mL; 1 h pretreatment) significantly enhanced the phosphorylation of Syk kinase in human B cells in a complement-dependent manner [1].
|
|---|---|
| ln Vivo |
GT103 (mouse-derived) (200 μg/mouse; intraperitoneal injection; three times a week; 2 weeks) inhibited the growth of CMT167 in C57BL/6 mice, increased the levels of tumor calreticulin and complement fragments, and upregulated genes related to B cell activation in tumors [1].
|
| Cell Assay |
Western Blot Analysis [1]
Cell Types: Human NCI-H460 large cell lung cancer cells; Human A549 lung adenocarcinoma cells Tested Concentrations: 200 μg/mL (containing 10% NHS) Incubation Duration: 2 hours Experimental Results: Compared with the control group without antibody, the normalized calreticulin intensity in H460 cells increased to 1.92. Compared with the control group without antibody, the normalized calreticulin intensity in A549 cells increased to 2.23. Compared with the IgG control group, plasma membrane calreticulin in both cell lines increased by approximately 2-fold. Total calreticulin expression in whole cell lysates remained unchanged. |
| Animal Protocol |
Animal/Disease Models:C57BL/6 (female, 6-8 weeks old, subcutaneously implanted with 2.0 × 10⁵ CMT167 lung cancer cells) [1]
Doses: 200 μg/mouse Route of Administration: Intraperitoneal injection; three times a week for 2 weeks Experimental Results: Tumor growth was reduced compared to the control group. The mean fluorescence intensity (MFI) of calreticulin in CMT167 tumors was increased. Deposition of C3b/iC3b/C3c fragments was increased in CMT167 tumors. The average levels of C3dg and C3d in CMT167 tumor lysates were increased, approximately twice that of the control group tumors. Upregulated genes in tumor B cells related to B cell MHC class II antigen presentation, antibody production, germinal center function and mature B cell survival. |
| References |
| Appearance |
Typically exists as solids at room temperature
|
|---|---|
| SMILES |
[GT103]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
